1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 18
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 20
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and Pathophysiology 22
3.1.1 Etiology 22
3.1.2 Pathophysiology 24
3.2 Symptoms 26
3.3 Quality of Life 27
4 Epidemiology 28
4.1 Disease Background 28
4.2 Risk Factors and Comorbidities 30
4.3 Global Trends 31
4.4 Forecast Methodology 32
4.4.1 Sources Used 32
4.4.2 Forecast Assumptions and Methods 33
4.4.3 Sources Not Used 40
4.5 Epidemiological Forecast for PsA (2015-2025) 41
4.5.1 Diagnosed Prevalent Cases of PsA 41
4.5.2 Age-Specific Diagnosed Prevalent Cases of PsA 43
4.5.3 Sex-Specific Diagnosed Prevalent Cases of PsA 45
4.5.4 Age-Standardized Diagnosed Prevalence of PsA 47
4.5.5 Diagnosed Prevalent Cases by Type 49
4.5.6 Diagnosed Prevalent Cases by Joint Involvement 50
4.6 Alternative Forecast of Diagnosed Prevalent Cases of PsA 50
4.7 Discussion 52
4.7.1 Epidemiological Forecast Insight 52
4.7.2 Limitations of the Analysis 53
4.7.3 Strengths of the Analysis 54
5 Disease Management 56
5.1 Diagnosis and Treatment Overview 56
5.1.1 Diagnosis 56
5.1.2 Disease Activity 58
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 59
5.1.4 Clinical Practice 68
5.2 US 70
5.3 5EU 71
5.4 Japan 74
6 Competitive Assessment 76
6.1 Overview 76
6.2 Product Profiles – Major Brands 77
6.2.1 Enbrel (etanercept) 77
6.2.2 Humira (adalimumab) 81
6.2.3 Simponi (golimumab) 85
6.2.4 Remicade (infliximab) 89
6.2.5 Cimzia (certolizumab pegol) 94
6.2.6 Cosentyx (secukizumab) 98
6.2.7 Lumicef (brodalumab) 102
6.2.8 Taltz (ixekizumab) 106
6.2.9 Stelara (ustekinumab) 109
6.2.10 Otezla (apremilast) 113
6.3 Other Therapeutic Classes 117
7 Unmet Needs and Opportunities 118
7.1 Overview 118
7.2 Increased Awareness Among Dermatologists and Primary Care Physicians 119
7.2.1 Unmet Need 119
7.2.2 Gap Analysis 120
7.2.3 Opportunity 121
7.3 Early Diagnosis and Treatment 122
7.3.1 Unmet Need 122
7.3.2 Gap Analysis 122
7.3.3 Opportunity 123
7.4 Improved Drug Safety and Efficacy Profiles 123
7.4.1 Unmet Need 123
7.4.2 Gap Analysis 125
7.4.3 Opportunity 126
7.5 Development of Cost-Effective Therapies 127
7.5.1 Unmet Need 127
7.5.2 Gap Analysis 128
7.5.3 Opportunity 129
8 Pipeline Assessment 130
8.1 Overview 130
8.2 Clinical Trial Mapping 130
8.2.1 Clinical Trials by Class 130
8.3 Promising Drugs in Clinical Development 131
8.3.1 Xeljanz (tofacitinib) 134
8.3.2 Orencia (abatacept) 140
8.3.3 Clazakizumab 146
8.4 Other Drugs in Development 151
8.5 Biosimilars 153
8.5.1 Introduction 153
8.5.2 Biosimilars Versus Branded Biologics in Key Autoimmune Diseases 154
8.5.3 Biosimilars in the Immunology Community 156
8.5.4 By the Numbers: Biosimilars in Development 156
8.5.5 The Impact of Biosimilars Will Be Felt Throughout the Pharmaceutical Industry 162
8.5.6 Uptake of Biosimilars is Expected to Vary by Market 162
9 Current and Future Players 165
9.1 Overview 165
9.2 Trends in Corporate Strategy 168
9.3 Company Profiles 169
9.3.1 Amgen 169
9.3.2 AbbVie 170
9.3.3 Johnson & Johnson 171
9.3.4 UCB 173
9.3.5 Novartis 174
9.3.6 Celgene 175
9.3.7 Pfizer 176
9.3.8 Bristol-Myers Squibb 177
9.3.9 AstraZeneca 178
9.3.10 Eli Lilly 179
9.3.11 Alder 180
10 Market Outlook 182
10.1 Global Markets 182
10.1.1 Forecast 182
10.1.2 Drivers and Barriers – Global Issues 185
10.2 US 187
10.2.1 Forecast 187
10.2.2 Key Events 191
10.2.3 Drivers and Barriers 192
10.3 5EU 192
10.3.1 Forecast 192
10.3.2 Key Events 196
10.3.3 Drivers and Barriers 197
10.4 Japan 197
10.4.1 Forecast 197
10.4.2 Key Events 200
10.4.3 Drivers and Barriers 201
11 Appendix 202
11.1 Bibliography 202
11.2 Abbreviations 213
11.3 Methodology 220
11.4 Forecasting Methodology 220
11.4.1 Diagnosed Psoriatic Arthritis Patients 220
11.4.2 Percent Drug-Treated Patients 220
11.4.3 Drugs Included in Each Therapeutic Class 221
11.4.4 Launch and Patent Expiry Dates 221
11.4.5 General Pricing Assumptions 222
11.4.6 Individual Drug Assumptions 223
11.4.7 Generic Erosion 227
11.4.8 Pricing of Pipeline Agents 228
11.5 Primary Research – Key Opinion Leaders Interviewed for This Report 229
11.6 Primary Research – Prescriber Survey 231
11.7 About the Authors 232
11.7.1 Analyst 232
11.7.2 Therapy Area Director 232
11.7.3 Epidemiologist 232
11.7.4 Global Director of Therapy Analysis and Epidemiology 233
11.8 About GlobalData 234
11.9 Disclaimer 234